Investors have pummeled GW stock recently, an analyst said, following recent concerns over prescriptions of its CBD oil, Epidiolex. Data suggest prescriptions slowed in early October. Read More...
Can This Biotech Stock Overcome Worries Plaguing Its Approved CBD Oil?
Investors have pummeled GW stock recently, an analyst said, following recent concerns over prescriptions of its CBD oil, Epidiolex. Data suggest prescriptions slowed in early October.
Add Comment